Program
Elecoglipron Test formulation 1 Dose A
Also written as “Elecoglipron Test formulation 1 Dose B”, “Elecoglipron Test formulation 2 Dose A” and “Elecoglipron Test formulation 2 Dose B”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by AstraZeneca.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 11 open or running | phase 1since Jul 20, 2026 | Jul 20, 2026 | Nov 18, 2026phase 1 · NCT07723833 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 20, 2026First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07723833 · 152 planned · United States
Ahead
- Nov 18, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2NCT07723833
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07723833Diabetes Mellitus, Type 2 · United States | 1 | Recruiting | Nov 18, 2026 | 152 |
How it is read
Names in the registry
- “Elecoglipron Test formulation 1 Dose A”, 1 entry
- “Elecoglipron Test formulation 1 Dose B”, 1 entry
- “Elecoglipron Test formulation 2 Dose A”, 1 entry
- “Elecoglipron Test formulation 2 Dose B”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.